2023 NICE 技术鉴定指导意见：派姆单抗联合化疗联合或不联合贝伐单抗治疗持续性、复发性或转移性宫颈癌[TA885].pdfVIP

Pembrolizumabplus

chemotherapywithor

withoutbevacizumabfor

persistet,recurretor

metastaticcervicalcancer

Technologyappraisalguidance

Published:3May2023

.uk/guidance/ta885

©NICE2023.Allrightsreserved.SubjecttoNoticeofrights(.uk/terms-and-

conditions#notice-of-rights).

Pembrolizumabpluschemotherapywithorwithoutbevacizumabforpersistent,recurrent

ormetastaticcervicalcancer(TA885)

Yourresponsibility

TherecommendationsinthisguidancerepresenttheviewofNICE,arrivedataftercareful

considerationof